Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
暂无分享，去创建一个
R. Salazar | I. Durán | D. Castellano | R. García-Carbonero | J. Capdevila | J. Sastre | V. Alonso | M. Llanos | I. Sevilla | J. M. Manzano Mozo | J. L. Manzano Mozo